Historical shareholding details of
Calamos Advisors LLC
holdings in Novo Nordisk - ADR (NVO)
Monthly changes of
Calamos Advisors LLC
shareholding in Novo Nordisk - ADR
over the previous
months
Month
|
Name |
Total no. shares held |
Percent Holding |
Mar 31, 2025
|
Calamos Advisors Llc
|
98,402
|
0.00%
|
|
Feb 28, 2025
|
Calamos Advisors Llc
|
98,402
|
0.00%
|
|
Jan 31, 2025
|
Calamos Advisors Llc
|
259,402
|
0.01%
|
|
Dec 31, 2024
|
Calamos Advisors Llc
|
146,866
|
0.00%
|
Dec 31, 2024
|
Calamos Advisors Llc
|
185,587
|
0.00%
|
|
Nov 30, 2024
|
Calamos Advisors Llc
|
185,587
|
0.00%
|
|
Oct 31, 2024
|
Calamos Advisors Llc
|
185,587
|
0.00%
|
|
Sep 30, 2024
|
Calamos Advisors Llc
|
220,619
|
0.00%
|
Sep 30, 2024
|
Calamos Advisors Llc
|
179,792
|
0.00%
|
|
Aug 31, 2024
|
Calamos Advisors Llc
|
184,127
|
0.00%
|
|
Jul 31, 2024
|
Calamos Advisors Llc
|
238,150
|
0.01%
|
|
Jun 30, 2024
|
Calamos Advisors Llc
|
304,343
|
0.01%
|
Jun 30, 2024
|
Calamos Advisors Llc
|
238,150
|
0.01%
|
|
May 31, 2024
|
Calamos Advisors Llc
|
238,150
|
0.01%
|
|
Apr 30, 2024
|
Calamos Advisors Llc
|
237,836
|
0.01%
|
|
Mar 31, 2024
|
Calamos Advisors Llc
|
308,341
|
0.01%
|
Mar 31, 2024
|
Calamos Advisors Llc
|
245,756
|
0.01%
|
|
Feb 29, 2024
|
Calamos Advisors Llc
|
245,756
|
0.01%
|
|
Jan 31, 2024
|
Calamos Advisors Llc
|
245,756
|
0.01%
|
|
Dec 31, 2023
|
Calamos Advisors Llc
|
323,754
|
0.01%
|
Dec 31, 2023
|
Calamos Advisors Llc
|
245,756
|
0.01%
|
|
Nov 30, 2023
|
Calamos Advisors Llc
|
252,806
|
0.01%
|
|
Oct 31, 2023
|
Calamos Advisors Llc
|
126,403
|
0.00%
|
|
Sep 30, 2023
|
Calamos Advisors Llc
|
332,338
|
0.01%
|
Sep 30, 2023
|
Calamos Advisors Llc
|
121,648
|
0.00%
|
|
Aug 31, 2023
|
Calamos Advisors Llc
|
121,727
|
0.01%
|
|
Jul 31, 2023
|
Calamos Advisors Llc
|
121,727
|
0.01%
|
|
Jun 30, 2023
|
Calamos Advisors Llc
|
166,410
|
0.01%
|
Jun 30, 2023
|
Calamos Advisors Llc
|
143,077
|
0.01%
|
|
May 31, 2023
|
Calamos Advisors Llc
|
141,027
|
0.01%
|
|
Mar 31, 2023
|
Calamos Advisors Llc
|
196,190
|
0.01%
|
View all ownership details of Novo Nordisk - ADR